Thrombocytopenia is frequently (22%) observed in a neonatal intensive care unit but the relative hemostatic risk imposed by the thrombocytopenia has not been extensively studied. We have conducted a prospective, comparative study of 97 consecutive neonates in the intensive care unit with platelet counts <100x10~/~ and 80 age and disease matched neonates with normal platelet counts ( > 150x10~/~). The clinical impact was assessed by: 1. a modified template bleeding time; 2. investigation for the presence of intraventricular hemorrhage (IVH) in infants <I500 gm and 3. evaluation of each infant for bleeding using a hemorrhage score (O-10) . This study demonstrated that thrombocytopenia is not only a laboratory abnormality but has a significant impact on the hemostatic integrity of the neonate. The bleeding time was inversely related to the platelet count and became progressively more prolonged when the platelet count fell below 100x10~/~. The frequency of IVH in the thrombocytopenic infants was 82% compared to 50% in the controls ( x~,~< 0.001). Clinical hemorrhage occurred in 86% of the thrombocytopenic infants compared to 35% of the controls ( x = ,~< 0.001) with the hemorrhage score being highest in infants with the most severe thrombocytopenia. Possible etiologic factors such as umbilical catheters, phototherapy, polycythemia, maternal or infant drugs and suspected or proven sepsis were equally distributed between both groups. This study demonstrates that thrombocytopenia in the neonate positively correlates with an increased risk of hemo. We have shown in previous studies that iodine 131-labeled monoclonal antibody (Mab) 3F8 could image human neuroblastoma (NB) xenografts in mice with excellent tumor to tissue ratios and could ablate such tumors with minimal toxicities. We now report our human imaging studies as the basis for targeting radiotherapy. Patients with NB were injected iv with 1.5 to 5 mCi iodine 131 labeled Mab 3F8. Serial gamma scannings were done. Tumor localization was apparent by 15 hours. Tissue radioactivity (uCi/cc) was calculated based on orthogonal gamma images. There was no focal uptake in the normal brain, liver, spleen or the adrenal gland. Tumor to nontumor ratios were 10-20:l between 15 to 140 hours after injection. Sites of uptake were confirmed as tumors at surgery in selected patients.Tumor to tissue ratio was 4-14: 1 for blood, 16-58:l for liver, 5-19:l for kidney, 10-36:l for red marrow, and 540-1940:l for CSF. In all patients sites of iodine uptake were consistent with tumor by conventional radiological studies. Deiodination with stomach excretion was significant. From tissue decay curves, relative radiation normal organs were 4-12% (to blood 37%) of the tumor dose>%oxicities included pain and shortness of breath, both being reversible. No hematological side effects were noted, The radiolabeled Mab 3F8 might have clinical potentials for the imaging and therapy of human neuroblastomas.
A "BILAYER-COUPLE" MECHANISM MEDIATES RBC

SHAPE ABNORMALITIES IN PATIENTS WITH CERTAIN CONGENITAL DISORDERS OF GLYCOLYSIS OR LIPID METABOLISM.
Robert Chilcote, (Spon. Marc 0. Beem), Univ Chicago, Wyler Children's Hosp, Chgo.
Characteristic echinocytic (E) RBC occur in hemolytic anemias caused by deficiency of the glycolytic enzymes TPI, PK, or GPI, while acanthocytosis (A) occurs in Hallervolden-Spatz disease and hypolipoproteinemia, but the basis for these shape abnormalities is unknown.
To determine whether the defect was intrinsic or induced by patient's plasma, combinations of RBC and plasma taken from patients and controls were incubated 90' at 3 7 ' .
Patient RBC were also incubated for 15' at OOC with chlorpromazine (CPZ), a membrane active amphipath known to reverse E produced in vitro. E and A were quantitated by microscopy. In all 5 disorders patient plasma failed to induce E/A in normal RBC and the E/A of patient cells persisted in normal plasma.
However, CPZ reversed both E and A of patient RBC (15-50% 1%). Shape correction was instantaneous at O°C, suggesting that CPZ acted by diffusion and did not influence cell metabolism.
According to the bilayer-couple hypothesis, the results also imply that these disorders alter the effective surface area of the membrane's interior leaflet relative to the exterior and provide a new model for investigation of these apparently diverse disorders.
REGULATION OF NEUTROPHIL PRODUCTION AT BOTH THE CFUc
898 AND MYELOCYTE LEVELS. RD Christensen and G Rothstein, (Spon. bv Michael A. Simmons) U o f Utah, SLC UT. The mechanisms f o i increasing n e u t r o p h i l ( n e u t ) production i n neonates are n o t c l e a r , b u t we p o s t u l a t e t h a t r e g u l a t i o n e x i s t n o t o n l y a t t h e CFUc, but a l s o a t t h e myelocyte l e v e l . W e p r e v iously observed r e g u l a t i o n a t t h e CFUc l e v e l i n non-infected neon a t a l r a t s , which had very r a p i d CFUc p r o l i f e r a t i o n (thymidine s u i c i d e >2 x a d u l t ) . However, during i n f e c t i o n , i n c o n t r a s t t o adults, t h e i r CFUc p r o l i f e r a t i v e r a t e d i d n o t increase f u r t h e r . I n t h e present study we devised an assay, r e q u i r i n g o n l y .05 ml blood, f o r neut myeloperoxidase (MPO) , an enzyme synthesized by promyelocytes and halved between daughter c e l l s w i t h each myeloc y t e d i v i s i o n . Thus, MPOImature neut can be a marker f o r the number o f myelocyte d i v i s i o n s . I n premature and term r a t s , MPOI neut was low (1.5+0. l~l o -~u n i t s l n e u t i n premature;1.5+0.7~10-7 u l n e u t a t term) b u t increased t o 3.0+0.4~10-' a t 3 wks and 5 . 8 + 0 . 7~1 0 -~ a t 6 wks, consistent w i t h e x t r a myelocyte d i v i s i o n s i n neonates, a m p l i f y i n g t h e i r production o f mature neut. During t h e f i r s t 24h o f a sublethal grog B streptococcal i n f e c t i o n , MPOIneut increased t o 4.0+0.6~10 ?u/neut i n neonates ( p <0.001), and from 3 . 9 + 0 . 5~1 0 -~ t o 6 . 5 + 0 . 8~1 0 -~ i n 4 wk-olds (p<0.005), l i k e l y from d e l e t i n g one myelocyte d i v i s i o n , thus shortening t h e time required t o produce mature neut. Therefore, i n non-infected growing neonates, neut production appears t o be accelerated by increasing t h e CFUc p r o l i f e r a t i v e r a t e and a m p l i f i e d by increasi n g t h e number o f myelocyte d i v i s i o n s . I n i n f e c t e d neonates, CFUc p r o l i f e r a t i o n i s n o t f u r t h e r accelerated, b u t production time i s shortened by d e l e t i n g one myelocyte d i v i s i o n . Endodermal sinus tumor is the most common form of germ cell malignancy found in the infantile testis. Histologically identical tumor may originate in extragonadal sites in young children, predominately in sacrococcygeal teratomas or presacral space. Extragonadal endodermal sinus tumors in young children appear to respond to cisplatinum (DDP) combinations, unlike the poor response reported in extragonadal, mainly mediastinal and retroperitoneal, germ cell tumors in the adolescent or adult. Treatment methods and results in six children with endodermal sinus tumor occurring in sacral sites are the subject of this report. All presented to Children's Hospital of Michigan (1975-82) between ages 12-31 months(median 20 mo) with unresectable or disseminated disease. Two of six underwent resection of a benign sacrococcygeal teratoma within the first month of life and returned with metastatic disease to lungs and retmperitoneal node or liver. Three children presented with previously undetected sacral mass, one with bone and lung metastases. Approach to the two without metastatic disease included vincristine-cyclophosphamide-dactinomycin; one survives disease free at nine years. The sixth child, the only male, presented with urinary retention secondary to presacral primary and multiple lung nodules; heis disease free at 32 months following four courses of DDP-velbanbleomycin. The remaining living child has had a 36 mo course of recurring disease responsive to four different DDP combinations. Exogenous growth hormone (GH) ( o i l U/kg/IM TIM) was administered t o 4 female p a t i e n t s w i t h Thalassemia Major (TM) and severe short s t a t u r e t o determine i f t h e i r growth r a t e would improve. A t t h e s t a r t o f t h e study, a l l were < l % i l e i n height, had a growth r a t e < 3 cmlyr, bone age < 12 y r s , n l TSH and T4 l e v e l s , n l GH response t o L-Dopa/glucagon, and had no previous therapy w i t h hormonal agents. A f t e r 6 months o f GH treatment, Pt.1 had an increase i n growth r a t e from 3 t o 4.8 cmlyr.
EXTRAGONADAL E N D O D E W SINUS TUMOR IN EARLY CHILD-
899
EFFECT OF EXNENOUS GROWM HORRNE IN PATIENTS WITH
Pt. 2 also had an increase i n growth r a t e (5.1 cmlyr); however t h e r e was a concurrent advancement i n puberty. Pts. 3 and 4 had no improvement i n growth v e l o c i t y . However, pt. 3 was found t o have a m i l d l y elevated TSH 3 months a f t e r GH was started. The data suggests t h a t treatment w i t h exogenous GH may be associated w i t h an improvement i n growth r a t e i n some TM patients.
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